Kristie L. Kahl

Tara Sweeney, BSN, RN, OCN, CHPN discussed best care for the health and well-being of a person across all stages of their cancer survivorship.

Aspirin use in patients with PI3K-mutated colorectal cancer helped to reduce disease recurrence, highlighting the importance of upfront genomic testing.

Patients newly diagnosed with multiple myeloma who are transplant ineligible or deferred may benefit from receiving a Darzalex treatment combination.

The risk for disease progression or death was reduced by 51% with subcutaneous Darzalex Faspro in certain patients with smoldering multiple myeloma.

Calquence plus Venclexta, with or without Gazyva, improved progression-free survival over the standard-of-care chemoimmunotherapy in patients with untreated chronic lymphocytic leukemia.

Long-term follow-data shows Revuforj to be effective in the treatment patients with R/R KMT2Ar acute leukemias.

For patients with transplant-ineligible or -deferred newly diagnosed multiple myeloma, the addition of Darzalex to VRd improved MRD responses as well as progression-free survival.

Following a CURE® Educated Patient® Lung Cancer Summit, the City of Hope expert answered 10 commonly asked questions from patients with lung cancer.

When compared with Zytiga, Xtandi appeared to have a lower incidence of infection among men with prostate cancer, especially those under 70 years.

Among patients with EGFR-mutated, advanced NSCLC, frontline treatment with Rybrevant plus Leclaza significantly prolonged progression-free survival.

Dato-DXd was efficacious in patients with non-small cell lung cancer with brain metastases who have certain gene alterations, a phase 2 study showed.

Patients with high-risk prostate cancer who had a higher dose of radiation plus long-term androgen deprivation therapy tended to live longer than those who had a lower dose.

Keytrida plus Lenvima improved survival and duration of response in patients with advanced hepatocellular carcinoma.

A nurse practitioner talks about personalized therapy and the role that genomic testing plays for patients with breast cancer.

Study findings support the use of a financial navigation program, in hopes of aiding patients with multiple myeloma affected by financial toxicity.

Brukinsa led to improved progression-free survival over Imbruvica in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma, follow-up from the phase 3 ALPINE study showed.

Research demonstrated comparable outcomes in the real-world setting and in the phase 2 MajesTEC-1 trial when it came to treatment with Tecvayli for relapsed or refractory myeloma.

A phase 3 trial demonstrated progression-free survival improvements with Tecentriq-chemotherapy combination in patients with endometrial carcinoma.

Researchers continue to investigate novel immunotherapy drugs for the treatment of renal cell carcinoma.

In this on-demand webinar series, CURE partnered with Look Good Feel Better to offer fun wig options for patients to wear after hair loss from cancer treatment.

In this on-demand webinar series, CURE partnered with Look Good Feel Better to discuss how patients with cancer can care for their wig.

In this on-demand webinar series, CURE partnered with Look Good Feel Better to show how patients who experienced hair loss from cancer treatment can style their wigs.

In this on-demand webinar series, CURE partnered with Look Good Feel Better to demonstrate how to put on and adjust a wig for comfort and appearance for patients with cancer who have experienced hair loss from treatment.

In this on-demand webinar series, CURE partnered with Look Good Feel Better to offer patients with cancer offered tips for haircare and hair loss before, during and after treatment.

In this on-demand webinar series, CURE partnered with Look Good Feel Better to demonstrate makeup techniques in applying foundation and blush to combat appearance-related side effect from cancer treatment.

Patients with HR-positive, HER2-negative high-risk early breast cancer tended to experience improved invasive disease and distant relapse-free survival after adding Verzenio to endocrine therapy.

In this on-demand webinar series, CURE partnered with Look Good Feel Better to discuss skincare during cancer treatment to assist patients in their daily routine.

In this on-demand webinar series, CURE partnered with Look Good Feel Better to discuss eyebrow shaping techniques and applying eye shadow and mascara to address appearance-related effect from cancer treatment.

In this on-demand webinar series, CURE partnered with Look Good Feel Better to discuss lip care as part of one’s makeup routine to address appearance-related effects from cancer.

Dato-DXd lengthened the average time it took patients with HR-positive, HER2-low or -negative metastatic breast cancer to experience disease progression, study results showed.